<DOC>
	<DOCNO>NCT01253525</DOCNO>
	<brief_summary>Investigate safety tolerability ramucirumab ( IMC-1121B ) drug product ( DP ) combination paclitaxel .</brief_summary>
	<brief_title>Study Weekly Paclitaxel With Ramucirumab Participants With Advanced Gastric Adenocarcinomas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Has histopathologically cytologically confirm diagnosis gastric gastroesophageal junction ( GEJ ) adenocarcinoma Has advance metastatic solid gastric adenocarcinoma fail standard therapy Has resolution clinically significant toxic effect prior therapy , surgery , treatment investigational agent device , treatment monoclonal antibody small molecule , radiotherapy chemotherapy . Has adequate organ function Eligible participant reproductive potential ( sex ) agree use adequate contraceptive method ( hormonal barrier method ) study period 12 week last dose study medication Has undergone major surgery within 28 day prior study , subcutaneous venous access device placement within 7 day prior study registration date Has elective plan surgery conduct trial Has treatment investigational agent device , antineoplastic small molecule , antineoplastic radiotherapy chemotherapy Was previously treat chemotherapy regimen contain nitrosoureas mitomycin C Has treatment antineoplastic monoclonal antibody within 8 week prior study registration date Has history deep vein thrombosis , pulmonary embolism , significant thromboembolism prior study registration date Has experience arterial thrombotic event , include myocardial infarction , cerebrovascular accident , transient ischemic attack , within 6 month prior study date Is receive therapeutic anticoagulation warfarin , lowmolecular weight heparin similar agent . ( Participants receive prophylactic , lowdose anticoagulation therapy eligible provide coagulation parameter International Normalized Ratio ( INR ) â‰¤ 1.5 , prothrombin time ( PT ) partial thromboplastin time ( PTT ) Is receive chronic therapy nonsteroidal antiinflammatory agent [ Aspirin use dose 325 milligrams/day ( mg/day ) permit ] Has significant bleeding disorder , vasculitis , history postoperative bleeding complication , hemoptysis significant bleeding episode gastrointestinal ( GI ) tract within 3 month prior study date Has history GI perforation and/or fistula within 6 month prior study date Has symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia Has uncontrolled arterial hypertension despite standard medical management . Has serious nonhealing wound peptic ulcer bone fracture within 28 day prior study date Has bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection , Crohn 's disease , ulcerative colitis , chronic diarrhea Has serious illness medical condition ( ) Is pregnant lactating Has receive treatment another investigational drug participation another interventional clinical trial within 28 day prior study date</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Gastroesophageal Junction</keyword>
</DOC>